Risk of Intracranial Hemorrhage with Tenecteplase in Acute Ischemic Stroke
Tenecteplase carries a symptomatic intracranial hemorrhage (sICH) risk of approximately 3-8.5% in acute ischemic stroke, which is similar to alteplase, though recent extended-window trials show rates of 2.8-3.0% for symptomatic ICH when used 4.5-24 hours after onset. 1, 2, 3
Hemorrhage Risk Profile
Standard Treatment Window (0-4.5 hours)
Symptomatic ICH: Occurs in approximately 3.09% of patients treated with tenecteplase versus 2.49% with alteplase, showing no statistically significant difference (RR = 1.21,95% CI 0.92-1.59) 4
Any ICH: Overall intracranial hemorrhage occurs in 13.22% with tenecteplase versus 12.72% with alteplase, demonstrating comparable safety profiles 4
Asymptomatic ICH: Observed in 8.68% of tenecteplase-treated patients versus 9.03% with alteplase 4
Extended Treatment Window (4.5-24 hours)
Recent high-quality trials demonstrate tenecteplase safety in extended windows:
OPTION trial (2026): Symptomatic ICH occurred in 2.8% of tenecteplase-treated patients versus 0% in controls when treating non-large vessel occlusion strokes 4.5-24 hours after onset 2
TRACE-III trial (2024): Symptomatic ICH rate of 3.0% with tenecteplase versus 0.8% with standard medical treatment in large vessel occlusion patients 4.5-24 hours after onset 3
BRIDGE-TNK trial (2025): When combined with thrombectomy, symptomatic ICH occurred in 8.5% of patients receiving tenecteplase plus thrombectomy versus 6.7% with thrombectomy alone 5
Real-World Data
The TETRIS registry (2024) provides the most comprehensive real-world hemorrhage data:
- Parenchymal hematoma (PH): 9.5% (95% CI 8.1-11.2) 6
- Any ICH: 39.4% (95% CI 36.8-42.1) 6
- Symptomatic ICH: 5.8% (95% CI 4.7-7.2) 6
Independent Predictors of Hemorrhage
Five key factors independently predict parenchymal hematoma after tenecteplase 6:
- Older age: aOR = 1.03 per year (95% CI 1.01-1.05)
- Male gender: aOR = 2.07 (95% CI 1.28-3.36)
- History of hypertension: aOR = 2.08 (95% CI 1.19-3.62)
- Higher baseline NIHSS: aOR = 1.07 per point (95% CI 1.03-1.10)
- Higher admission blood glucose: aOR = 1.12 per unit (95% CI 1.05-1.19)
Dose-Related Considerations
No significant difference in hemorrhage risk exists between 0.25 mg/kg and 0.4 mg/kg tenecteplase doses when compared to alteplase 4. The 2018 AHA/ASA guidelines note that 0.4 mg/kg tenecteplase has a safety profile similar to alteplase in patients with predominantly minor neurological impairment 1.
Clinical Outcomes of Hemorrhage
Parenchymal hematoma significantly worsens outcomes 6:
- Associated with poorer functional outcomes at 3 months (p < 0.0001)
- Significantly increases mortality (p < 0.0001)
Hemorrhage Location Distribution
The distribution of hemorrhage types is similar between tenecteplase and alteplase, with no significant differences in 4:
- Intraventricular hemorrhage
- Subarachnoid hemorrhage
- Hemorrhagic infarction
- Parenchymal hematoma
- Remote parenchymal hematoma
Critical Safety Caveat
Rare but catastrophic simultaneous intracranial and spinal hemorrhage can occur, even without pre-existing vascular anomalies or coagulopathy 7. While this represents an extremely rare complication, clinicians must maintain vigilance for both cranial and spinal hemorrhagic complications.
Guideline Recommendations
The 2018 AHA/ASA guidelines establish that tenecteplase at 0.4 mg/kg might be considered as an alternative to alteplase in patients with minor neurological impairment and no major intracranial occlusion (Class IIb, LOE B-R) 1. The safety profile appears similar to alteplase, though superiority or noninferiority has not been definitively proven 1.
Blood pressure must be maintained <180/105 mm Hg for at least 24 hours after tenecteplase administration to minimize hemorrhage risk (Class I, LOE B-NR) 1.